(
)
212
K. Saeki et al.rMutation Research 441 1999 205–213
assessed by an in vivo mutagenesis assay using lacZ trans-
O-acetyltransferase. In any way, further studies are
needed for better understanding the mechanism of
induction of the NQ mutagenicity.
In conclusion, the present study with a series of
fluorine-substituted NQs provides further basic data
for possible mutagenic modification by fluorine-sub-
stitution and may offer a tool for mechanistic studies.
Ž
.
genic mice, Mutat. Res. 414 1998 165–169.
w
w
x
12 K. Hirao, Y. Shinohara, H. Tsuda, S. Fukushima, M. Taka-
hashi, N. Ito, Carcinogenic activity of quinoline on rat liver,
Ž
.
Cancer Res. 36 1976 329–335.
x
13 Y. Shinohara, T. Ogiso, M. Hananouchi, K. Nakanishi, T.
Yoshimura, N. Ito, Effect of various factors on the induction
of liver tumors in animals by quinoline, Jpn. J. Cancer Res.
Ž
.
68 1977 785–796.
w
x
14 E.H. Wayand, J. Defauw, C.A. McQueen, C.L. Meschter,
S.K. Meegalla, E.J. LaVoie, Bioassay of quinoline, 5-fluoro-
quinoline, carbazole, 9-methylcarbazole and 9-ethylcarbazole
Ž
.
in newborn mice, Food Chem. Toxicol. 31 1993 707–715.
References
w
w
w
x
15 M. Nagao, T. Yahagi, Y. Seino, T. Sugimura, N. Ito, Muta-
genicities of quinoline and its derivatives, Mutat. Res. 42
w x
1
Ž
.
E.J. LaVoie, L. Tulley-Freiler, V. Bedenko, D. Hoffmann,
Mutagenicity of substituted phenanthrenes in Salmonella ty-
1977 335–342.
x
16 M. Nagao, T. Sugimura, Molecular biology of the carcino-
Ž
.
phinurium, Mutat. Res. 116 1983 91–102.
Ž
.
gen, 4-nitroquinoline 1-oxide, Adv. Cancer Res. 23 1976
w x
2
S.S. Hecht, E.J. LaVoie, V. Bedenko, L. Pingaro, S.
Katayama, D. Hoffmann, D.J. Sardella, E. Boger, R.E. Lehr,
Reduction of tumorigenicity and of dihydrodiol formation by
131–169.
x
17 M. Tada, K.H. Kohda, Y. Kawazoe, Biomimetic preparation
and structure determination of QG, one of the quinoline-DNA
base adducts formed in cells treated with 4-nitroquinoline
1-oxide, Jpn. J. Cancer Res. Gann 75 1984 976–985.
18 K. Fukuhara, A. Hakura, N. Sera, H. Tokiwa, N. Miyata, 1-
w
x
fluorine substitution in the angular rings of dibenzo a,i -
pyrene, Cancer Res. 41 1981 4341–4345.
Ž
.
Ž
.
Ž
.
w x
3
w
x
E. Hubenman, T.J. Slag, Mutagenicity and tumor-initiating
activity of fluorinated derivatives of 7,12-dimethyl-
w x
and 3-nitro-6-azabenzo a pyrene and their N-oxide; highly
mutagenic nitrated azaarenes, Chem. Res. Toxicol. 5 1992
w x
Ž
.
benz a anthracene, Cancer Res. 39 1979 411–414.
Ž
.
w x
4
L. Diamond, K. Chain, R.G. Harvey, J. DiGiovanni, Muta-
genic activity of methyl- and fluoro-substituted derivatives of
polycyclic aromatic hydrocarbons in a human hepatoma
149–153.
w
w
x
19 N. Sera, K. Fukuhara, N. Miyata, K. Horikawa, H. Tokiwa,
w x
Mutagenicity of nitro-azabenzo a pyrene and its related com-
Ž
.
cell-mediated assay, Mutat. Res. 136 1984 65–72.
Ž
.
pounds, Mutat. Res. 280 1992 81–85.
w x
5
E.C. Miller, J.A. Miller, The carcinogenicity of fluoro deriva-
tives of 10-methyl-1,2-benzanthracene: 3- and 4-monofluoro
x
20 A. Roe, G.F. Hawkins, The preparation of heterocyclic fluo-
rine compounds by the Schiemann reaction: II. The monoflu-
Ž
.
derivatives, Cancer Res. 20 1960 133–137.
Ž
.
oroquinolines, J. Am. Chem. Soc. 71 1949 1785–1786.
w x
6
K. Takahashi, M. Kamiya, Y. Sengoku, K. Kohda, Y. Kawa-
zoe, Deprivation of the mutagenic property of quinoline:
inhibition of mutagenic metabolism by fluorine substitution,
w
w
x
21 M.H. Palmer, The Skraup reaction: formation of 5- and
7-substituted quinolines, J. Chem. Soc. 1962 3645–3652.
22 M. Bellas, H. Suschitzky, Heterocyclic fluorine compounds:
Ž
.
x
Ž
.
Chem. Pharm. Bull. 36 1988 4630–4633.
V. Fluororyridine oxides and fluoroquinoline N-oxides, J.
w x
7
M. Kamiya, Y. Sengoku, K. Takahashi, K. Kohda, Y. Kawa-
zoe, Antimutagenic structure modification of quinoline: Fluo-
rine-substitution at position-3, in: Y. Kuroda, D.M. Shankel,
Ž
.
Chem. Soc. 1963 4007–4009.
w
w
x
23 J.H. Wilkinson, I.L. Finar, Properties of fluorine-substituted
5-aminoacridines and related compounds: III. Some 5-amino-
1,2,2 ,3 -pyridoacridines, J. Chem. Soc. 1948 288–291.
24 B.N. Ames, J. McCann, E. Yamazaki, Methods for detecting
X
X
Ž
.
M.D. Waters Eds. , Antimutagenesis and Anticarcinogene-
sis, Vol. II, Plenum, New York, 1990, pp. 441–446.
Ž
.
x
w x
8
K. Saeki, K. Takahashi, Y. Kawazoe, Metabolism of muta-
genicity-deprived 3-fluoroquinoline: comparison with muta-
carcinogens and mutagens with the Salmonellarmamma-
lian-microsome mutagenicity test, Mutat. Res. 31 1975
Ž
.
Ž
.
genic quinoline, Biol. Pharm. Bull. 16 1993 232–234.
K. Saeki, H. Kawai, Y. Kawazoe, A. Hakura, Dual stimula-
tory and Inhibitory effects of fluorine-substitution on muta-
genicity: an extension of the enamine epoxide theory for
activation of the quinoline nucleus, Biol. Pharm. Bull. 20
347–363.
w x
9
w
x
25 K. Takahashi, T. Kaiya, Y. Kawazoe, Structure–mutagenic-
ity relationship among aminoquinolines, aza-analogues of
naphthylamine, and their N-acetyl derivatives, Mutat. Res.
Ž
.
187 1987 191–197.
Ž
.
1997 646–650.
w
x
26 A. Hakura, Y. Tsutsui, H. Mochida, Y. Sugihara, T. Mikami,
F. Sagami, Mutagenicity of dihydroxybenzenes and dihy-
droxynaphthalenes for Ames Salmonella tester strains, Mu-
tat. Res. 371 1996 293–299.
27 H.S. Rosenkranz, R. Mermelstein, Mutagenicity and geno-
w
w
x
10 K. Saeki, M. Kadoi, Y. Kawazoe, M. Futakuchi, D. Ti-
wawech, T. Shirai, Modification of the carcinogenic property
of quinoline, a hepatocarcinogen, by fluorine atom substitu-
tion: evaluation of carcinogenicity by a medium-term assay,
Ž
.
w
x
Ž
.
Biol. Pharm. Bull. 20 1997 40–43.
toxicity of nitroarenes: all nitro-containing chemicals were
x
11 Y. Miyata, K. Saeki, Y. Kawazoe, M. Hayashi, T. Sofuni, T.
Suzuki, Antimutagenic structural modification of quinoline
Ž
.
not created equal, Mutat. Res. 114 1983 217–267.
w
x
28 E.C. McCoy, H.S. Rosenkranz, R. Mermelstein, Evidence for